Isofol has initiated five additional study sites in the ISO-CC-005 study in which Modufolin® is evaluated in colorectal cancer
Isofol Medical AB (publ) announced today that the last one of five additional study sites was initiated in Greece and is now ready to start inclusion in the ISO-CC-005 study. The study sites were initiated in order to ensure the planned recruitment rate in the study and to offer additional investigators opportunity to familiarize themselves with the Modufolin® treatment prior the upcoming pivotal study, ISO-CC-007, scheduled to start late 2017.ISO-CC-005 is a Phase I/II open-label, multicenter clinical trial designed to identify the Modufolin® dose to be used in continued clinical